[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
3. Hauser J, Homann HH, Drücke D, Kuhnen C, Esenwein SA, Steinau HU: [Desmoplastic neurotropic melanoma. Diagnosis and therapeutic procedures for a rare clinical entity]. Chirurg; 2006 Oct;77(10):939-42
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Desmoplastic neurotropic melanoma. Diagnosis and therapeutic procedures for a rare clinical entity].
  • [Transliterated title] Spindelzelliges desmoplastisches Melanom. Ein seltenes Krankheitsbild--Diagnostik und therapeutisches Vorgehen.
  • Desmoplastic neurotropic melanoma is an exceedingly rare variant of the malignant melanomas.
  • These melanomas mostly occur on the head, neck, and face, and a wide local excision of the tumor is probably the most important prognostic factor.
  • Therefore, in most cases the tumor resections result in large tissue defects.
  • In this paper, a 79-year-old patient with a basal cell carcinoma and desmoplastic melanoma on the scalp is described, and the therapeutic procedure is discussed.
  • [MeSH-major] Melanoma / surgery. Neoplasms, Multiple Primary / surgery. Scalp / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Diagnosis, Differential. Female. Humans. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Reoperation. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1971 Oct;28(4):914-36 [5286448.001]
  • [Cites] Aust N Z J Surg. 1990 Dec;60(12):967-72 [2268214.001]
  • [Cites] Cancer. 2004 Feb 1;100(3):598-604 [14745878.001]
  • [Cites] Pathology. 2004 Oct;36(5):445-51 [15370114.001]
  • [Cites] J Neurooncol. 1992 Jun;13(2):165-71 [1331344.001]
  • [Cites] World J Surg. 1992 Mar-Apr;16(2):186-90 [1373257.001]
  • [Cites] Am J Surg. 2001 Dec;182(6):590-5 [11839322.001]
  • [Cites] Ann Surg Oncol. 2003 May;10(4):403-7 [12734089.001]
  • [Cites] Semin Cutan Med Surg. 1997 Jun;16(2):131-6 [9220552.001]
  • [Cites] Cancer. 1987 Nov 1;60(9):2269-74 [3440236.001]
  • [Cites] Head Neck. 2002 Dec;24(12):1068-71 [12454945.001]
  • (PMID = 16425057.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


Advertisement
4. Sedda AF, Rossi G, Cipriani C, Carrozzo AM, Donati P: Dermatological high-dose-rate brachytherapy for the treatment of basal and squamous cell carcinoma. Clin Exp Dermatol; 2008 Nov;33(6):745-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermatological high-dose-rate brachytherapy for the treatment of basal and squamous cell carcinoma.
  • BACKGROUND: Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are among the most common cancers in humans.
  • METHODS: In total, 53 patients with histologically confirmed diagnosis of BCC and of SCC were enrolled for the treatment.
  • Histological examination confirmed complete tumour regression.
  • [MeSH-major] Brachytherapy / methods. Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Facial Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Skin Neoplasms / radiotherapy
  • [MeSH-minor] Beta Particles / therapeutic use. Face. Female. Follow-Up Studies. Humans. Male. Nose Neoplasms / radiotherapy. Ointments. Radiotherapy Dosage. Remission Induction. Rhenium / therapeutic use

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18681873.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ointments; 7440-15-5 / Rhenium
  •  go-up   go-down


5. Clément C, Lebreuilly I, Stephan A, De Raucourt S, Dutriaux C, Comoz F, Leroy D, Verneuil L: [Intracranial extension of cutaneous facial squamous cell carcinoma: involvement of the neurotropic pathway]. Ann Dermatol Venereol; 2010 Aug-Sep;137(8-9):551-4
Hazardous Substances Data Bank. CETUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intracranial extension of cutaneous facial squamous cell carcinoma: involvement of the neurotropic pathway].
  • [Transliterated title] Extension intracrânienne d'un carcinome spinocellulaire de la face : implication de la voie neurotrope.
  • BACKGROUND: Squamous cell carcinoma is the most common form of skin cancer after basal cell carcinoma.
  • It comprises locoregional malignant tumours with more rapid and severe spread, and which may metastasise through blood or lymph, and through a less well-known neurotropic pathway.
  • We report a case of late and slowly progressive recurrence of squamous cell carcinoma revealed and characterized by neurological symptoms alone.
  • OBSERVATION: A 69-year-old woman with a history of cutaneous squamous cell carcinoma on the left nostril edge removed 10 years earlier presented right trigeminal neuralgia in 2003.
  • Deep biopsy allowed a diagnosis of invasive squamous cell carcinoma to be made.
  • DISCUSSION: Neurotropism is an important feature of squamous cell carcinoma, and reveals the aggressive nature of this condition.
  • This feature makes it hard to diagnose relapse since the neurological symptoms may be isolated for a long period, hence the need for systematic screening for perineural tumour sites on histological analysis of the initial lesion.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Facial Neoplasms / pathology. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Aged. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Biopsy. Bone Neoplasms / secondary. Cavernous Sinus / pathology. Cetuximab. Combined Modality Therapy. Cranial Nerve Diseases / etiology. Female. Humans. Magnetic Resonance Imaging. Neuralgia / etiology. Organ Specificity. Paresthesia / etiology. Receptor, Epidermal Growth Factor / immunology. Trigeminal Nerve / pathology. Zygoma / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20804901.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  •  go-up   go-down


6. Galletly NP, McGinty J, Dunsby C, Teixeira F, Requejo-Isidro J, Munro I, Elson DS, Neil MA, Chu AC, French PM, Stamp GW: Fluorescence lifetime imaging distinguishes basal cell carcinoma from surrounding uninvolved skin. Br J Dermatol; 2008 Jul;159(1):152-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence lifetime imaging distinguishes basal cell carcinoma from surrounding uninvolved skin.
  • OBJECTIVES: To establish whether FLIM of skin autofluorescence can provide useful contrast between basal cell carcinomas (BCCs) and surrounding uninvolved skin.
  • METHODS: Unstained excision biopsies of 25 BCCs were imaged en face with FLIM following excitation of autofluorescence with a 355 nm pulsed ultraviolet laser.
  • RESULTS: Using FLIM we were able to distinguish areas of BCC from surrounding skin in an ex vivo study.
  • Significant reductions in mean fluorescence lifetimes between areas of BCC and areas of surrounding uninvolved skin were demonstrated (P < 0.0001).
  • Conversely, there was no significant difference between the BCC and uninvolved areas of each sample when mean autofluorescence intensities were examined.
  • Moreover, wide-field false-colour images of fluorescence lifetimes clearly discriminated areas of BCC from the surrounding uninvolved skin.
  • CONCLUSIONS: We therefore believe that FLIM has a potential future clinical role in imaging BCCs for rapid and noninvasive tumour delineation and as an aid to determine adequate excision margins with best preservation of normal tissue.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Diagnostic Imaging / methods. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Contrast Media. Female. Fluorescence. Humans. Male. Middle Aged. Neoplasm Staging / methods. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18460029.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


7. Gabillot-Carré M, Weill F, Mamelle G, Kolb F, Boitier F, Petrow P, Ortoli JC, Margulis A, Souteyrand P, Mercier S, Spatz A, Duvillard P, Validire P, Avril MF: Microcystic adnexal carcinoma: report of seven cases including one with lung metastasis. Dermatology; 2006;212(3):221-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Microcystic adnexal carcinoma (MAC) is a rare cutaneous neoplasm, with a high rate of local recurrences.
  • RESULTS: The primary MAC were located on the face in all patients, and 85% were initially misdiagnosed.
  • In 3 patients, the course of the disease was severe: one of them developed pathologically proven lung metastasis.
  • CONCLUSION: The present study and review of the literature confirm the clinically aggressive evolution of MAC and its rare ability to give rise to metastasis.
  • [MeSH-major] Carcinoma, Skin Appendage / pathology. Facial Neoplasms / pathology. Lung Neoplasms / secondary. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Carcinoma, Basal Cell / diagnosis. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Microcystic adnexal carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 S. Karger AG, Basel
  • (PMID = 16549917.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


8. McPherson T, Ogg G: Spontaneous resolution of basal cell carcinoma in naevoid basal cell carcinoma syndrome/Gorlin's syndrome. Clin Exp Dermatol; 2009 Dec;34(8):e884-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous resolution of basal cell carcinoma in naevoid basal cell carcinoma syndrome/Gorlin's syndrome.
  • We describe a 10-year-old patient with naevoid basal cell carcinoma syndrome (NBCCS) which was diagnosed when she was 3 years old.
  • She has developed multiple basal cell carcinomas (BCCs) over this time, in particular on her face and trunk.
  • This phenomenon has not previously been reported and we believe that it could be important for understanding lesional biology and for future approaches to management.
  • [MeSH-major] Basal Cell Nevus Syndrome / pathology. Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Child. Female. Humans. Neoplasm Regression, Spontaneous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20055856.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Zghal M, Triki S, Elloumi-Jellouli A, Jbali A, Gargouri H, Benmously R, Souissi R, Chedly I, Brahim EB, Ayed MB, Fenniche S, Mokhtar I: [Contribution of the cryosurgery in the management of xeroderma pigmentosum]. Ann Dermatol Venereol; 2010 Oct;137(10):605-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] L'apport de la cryochirurgie dans la prise en charge du xeroderma pigmentosum.
  • BACKGROUND: Basal cell carcinoma (BCC) occurs frequently in young patients with xeroderma pigmentosum (XP).
  • Because tumours are multiple and usually found on the face, alternatives to surgery are proposed.
  • The purpose of this study was to evaluate the efficacy of cryosurgery for BCC in XP patients.
  • PATIENTS AND METHODS: This was a retrospective study that included all instances of BCC occurring in XP patients treated by cryosurgery between January 2002 and October 2008.
  • RESULTS: Forty-five cases of primary facial BCC and one case of relapsing BCC (16 on the cheeks, 11 on the nose, six on the face and five on the inner edge of the eye area) were treated by cryosurgery in 18 XP patients (average age: 18.7 years; sex ratio: 0.5).
  • CONCLUSION: Because of its simplicity, its good safety, its sparing of skin and its reliability of oncological outcome, cryosurgery is the treatment of choice for CBC in XP patients.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Cryosurgery / methods. Facial Neoplasms / surgery. Head and Neck Neoplasms / surgery. Skin Neoplasms / surgery. Xeroderma Pigmentosum / surgery
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / surgery. Reoperation. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Xeroderma pigmentosum.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Masson SAS.
  • (PMID = 20932439.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


10. Zbar RI, Canady JW: MOC-PSSM CME article: Nonmelanoma facial skin malignancy. Plast Reconstr Surg; 2008 Jan;121(1 Suppl):1-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MOC-PSSM CME article: Nonmelanoma facial skin malignancy.
  • Identify the environmental and genetic risk factors in developing nonmelanoma facial skin malignancy.
  • 2. Understand the proper evaluation of a patient presenting with nonmelanoma facial skin malignancy.
  • 3. Outline the various treatment options available for patients with nonmelanoma facial skin malignancy and understand the specific technique of Mohs' micrographic surgery versus surgical excision with frozen section control.
  • BACKGROUND: The incidence of nonmelanoma facial skin malignancy is rising dramatically.
  • METHODS: A literature review was performed regarding the evaluation and various management options for patients with nonmelanoma facial skin malignancy.
  • RESULTS: An algorithm is presented regarding the appropriate assessment and treatment of patients with nonmelanoma facial skin malignancy.
  • Comparison of the Mohs' technique with frozen section control showed potentially similar disease-free outcomes.
  • CONCLUSIONS: Various treatment algorithms exist for nonmelanoma facial skin malignancy.
  • Consideration must be given by the physician to patient comorbidities, anesthesia requirements, appropriate monitoring, and cost of excision.
  • [MeSH-major] Carcinoma / surgery. Face. Mohs Surgery / adverse effects. Reconstructive Surgical Procedures / methods. Skin Neoplasms / surgery
  • [MeSH-minor] Anesthesia. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Frozen Sections. Humans. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / surgery. Risk Factors. Surgical Flaps. Treatment Outcome. Wound Healing

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18182960.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


11. Zamanian A, Farshchian M, Meheralian A: A 10-year study of squamous cell carcinoma in Hamedan in the west of Iran (1993-2002). Int J Dermatol; 2006 Jan;45(1):37-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 10-year study of squamous cell carcinoma in Hamedan in the west of Iran (1993-2002).
  • BACKGROUND: Cutaneous squamous cell carcinoma (SCC) is the second most common form of skin cancer in Caucasians.
  • METHODS: This descriptive cross-sectional study was carried out in patients diagnosed with SCC in the Department of Dermatology, Hamedan Sina Hospital, Hamedan, Iran, in the 10-year period from 1993 to 2002.
  • RESULTS: From a total of 6846 biopsies, 669 skin cancers were diagnosed, including 449 (66.67%) basal cell carcinomas (BCC) and 179 (26.76%) SCC.
  • The head and face were the most common sites of SCC location.
  • CONCLUSION: SCC is the second most common form of skin malignancy in the west of Iran.
  • Sunlight may play a role in the etiology of this tumor.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / epidemiology. Skin Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Biopsy, Needle. Child. Child, Preschool. Cross-Sectional Studies. Developing Countries. Female. Humans. Incidence. Iran / epidemiology. Male. Middle Aged. Neoplasm Staging. Prognosis. Risk Assessment. Sex Distribution. Time Factors

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16426373.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Czakó L, Tiszlavicz L, Takács R, Baradnay G, Lonovics J, Cserni G, Závodná K, Bartosova Z: [The first molecular analysis of a Hungarian HNPCC family: a novel MSH2 germline mutation]. Orv Hetil; 2005 May 15;146(20):1009-16
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hereditary nonpolyposis colorectal cancer is an inherited disease characterized by onset at an early age, an excess of synchronous and metachronous large bowel tumors and a variety of extracolorectal malignancies.
  • Basal and squamous cell carcinomas of the skin are not customarily included in the tumor spectrum of the syndrome.
  • The disease is caused by a germline mutation in one of the DNA mismatch repair genes, most commonly MSH2 or MLH1, and typically presents with microsatellite instability and frequent loss of mismatch repair protein expression in the tumor tissue.
  • PATIENT: The case of a 62-year old woman who had a history of colon cancer at the age of 46 years, endometrial cancer at the age of 56 years, baso-squamous, and squamous cell cancer of the face at the ages of 53, 54, 62 and 58 years, respectively, and rectal cancer at 60 is reported.
  • Her family fulfills the Amsterdam criteria for the diagnosis of hereditary nonpolyposis colorectal cancer.
  • The baso-squamous cell, the squamous cell, the endometrial and the rectal cancers were assessed for the microsatellite instability status and the expression of the MSH2 and MLH1 mismatch repair proteins, and the p53 tumor suppressor protein by immunohistochemistry.
  • The immunohistochemical staining in the baso-squamous cell, the squamous cell, the rectal and endometrial cancers were negative for MSH2 and positive for MLH1 proteins.
  • DNA sequencing analysis revealed a mutation c.2292G > A in exon 14 of the MSH2 gene, which is altering the 764. amino acid, the tryptophan to STOP codon (p.W764X).
  • According to the Human Mutation Database and International Collaborative Group of HNPCC Database, this mutation is novel, has not been reported previously.
  • Cutaneous baso-squamous and squamous cell cancers may present as part of the HNPCC phenotype.
  • Detection of the loss of mismatch repair protein expression and mismatch repair gene mutation mapping, represents a significant improvement of the diagnosis of this syndrome in Hungary.
  • [MeSH-major] Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. DNA-Binding Proteins / genetics. Germ-Line Mutation. Neoplasm Proteins / genetics. Nuclear Proteins / genetics. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Aged. Base Pair Mismatch. Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / genetics. Carrier Proteins. DNA Mutational Analysis. DNA Repair. DNA, Neoplasm / analysis. Decision Trees. Endometrial Neoplasms / genetics. Female. Genetic Testing. Humans. Hungary. Immunohistochemistry. Male. Microsatellite Repeats. Middle Aged. MutS Homolog 2 Protein. Pedigree

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15945244.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / MLH1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


13. Haneke E: [Precancerous and early invasive carcinomas: non-surgical treatment of head and facial skin]. HNO; 2009 Apr;57(4):315-23
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Precancerous and early invasive carcinomas: non-surgical treatment of head and facial skin].
  • This causes a field cancerization effect frequently with multiple actinic keratoses (AKs), basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs).
  • The most important aspect, however, is the prophylaxis of chronic photodamage.
  • [MeSH-major] Facial Neoplasms / diagnosis. Facial Neoplasms / therapy. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / therapy. Precancerous Conditions / diagnosis. Precancerous Conditions / therapy. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy
  • [MeSH-minor] Dermatology / trends. Humans. Neoplasm Invasiveness. Otolaryngology / trends

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Eur Acad Dermatol Venereol. 2006 Aug;20(7):877-8 [16898919.001]
  • [Cites] Arch Dermatol. 2003 Jul;139(7):943-4 [12873902.001]
  • [Cites] Arch Dermatol. 2003 Jul;139(7):944-5 [12873903.001]
  • [Cites] Dermatol Surg. 2006 Mar;32(3):380-6 [16640683.001]
  • [Cites] Australas J Dermatol. 2006 Aug;47(3):186-8 [16867000.001]
  • [Cites] Vaccine. 2004 Apr 16;22(13-14):1799-809 [15068864.001]
  • [Cites] Int J Pharm. 2008 Apr 2;353(1-2):233-42 [18191509.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12(6):562-4 [12459528.001]
  • [Cites] Jpn J Ophthalmol. 2006 Jul-Aug;50(4):305-11 [16897213.001]
  • [Cites] J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):414-8 [10459115.001]
  • [Cites] Dermatol Surg. 2005 Mar;31(3):371-4 [15841646.001]
  • [Cites] Arch Dermatol. 2006 Jun;142(6):729-35 [16785375.001]
  • [Cites] Arch Dermatol. 1998 Feb;134(2):207-14 [9487213.001]
  • [Cites] N Engl J Med. 1999 Dec 2;341(23):1767-8 [10610445.001]
  • [Cites] Curr Opin Oncol. 2005 Mar;17(2):160-6 [15725922.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Feb 6;314(2):313-20 [14733907.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):33-40 [14732657.001]
  • [Cites] Clin Exp Dermatol. 2006 Sep;31(5):721-2 [16780500.001]
  • [Cites] J Drugs Dermatol. 2005 Nov-Dec;4(6):708-17 [16302556.001]
  • [Cites] Drugs. 2006;66(13):1657-64 [16978032.001]
  • [Cites] Arch Dermatol. 2002 Sep;138(9):1165-71 [12224977.001]
  • [Cites] Arch Dermatol. 2003 Jul;139(7):945-7 [12873904.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2359s-2365s [16609059.001]
  • [Cites] Cancer Biol Ther. 2006 Jun;5(6):674-83 [16855373.001]
  • [Cites] Dermatol Online J. 2006 Mar 30;12(3):25 [16638439.001]
  • [Cites] Arch Dermatol. 2001 Mar;137(3):319-24 [11255332.001]
  • [Cites] Dermatol Surg. 2008 Jul;34(7):859-72 [18363724.001]
  • [Cites] J Am Acad Dermatol. 1998 Mar;38(3):438-42 [9520026.001]
  • [Cites] Semin Cutan Med Surg. 2008 Mar;27(1):52-62 [18486025.001]
  • [Cites] J Am Acad Dermatol. 2006 Nov;55(5):849-61 [17052492.001]
  • [Cites] J Am Acad Dermatol. 2002 Sep;47(3):390-8 [12196749.001]
  • [Cites] Clin Exp Dermatol. 2005 Nov;30(6):717-8 [16197401.001]
  • [Cites] Exp Dermatol. 2006 Sep;15(9):742-50 [16881970.001]
  • [Cites] Br J Dermatol. 2007 Feb;156(2):320-8 [17223873.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7545-52 [15492281.001]
  • [Cites] J Am Acad Dermatol. 2007 Mar;56(3):422-5 [17184874.001]
  • [Cites] Eur J Dermatol. 2000 Oct-Nov;10(7):568-75; discussion 576 [11056436.001]
  • [Cites] Br J Dermatol. 2005 Apr;152(4):765-72 [15840111.001]
  • [Cites] Br J Dermatol. 2006 Nov;155(5):1029-36 [17034536.001]
  • [Cites] J Invest Dermatol. 2006 Feb;126(2):265-71 [16374471.001]
  • [Cites] Clin Exp Dermatol. 2002 Oct;27(7):571-7 [12464152.001]
  • [Cites] Clin Exp Dermatol. 2003 Nov;28 Suppl 1:13-5 [14616805.001]
  • [Cites] Eur J Dermatol. 2004 Mar-Apr;14 (2):96-102 [15196999.001]
  • [Cites] Cancer. 2008 Jun 15;112(12):2635-45 [18442098.001]
  • [Cites] Clin Exp Dermatol. 2006 Sep;31(5):717-8 [16901322.001]
  • [Cites] Eur J Dermatol. 2006 Jul-Aug;16(4):335-9 [16935787.001]
  • [Cites] J Am Acad Dermatol. 2008 Apr;58(4):585-91 [18068265.001]
  • [Cites] Dermatol Clin. 2007 Jan;25(1):81-7 [17126745.001]
  • [Cites] J Drugs Dermatol. 2003 Dec;2(6):629-35 [14711141.001]
  • [Cites] Apoptosis. 2004 May;9(3):291-8 [15258460.001]
  • [Cites] J Am Acad Dermatol. 2006 Dec;55(6):1092-4 [17097406.001]
  • [Cites] Nature. 2000 Aug 31;406(6799):1005-9 [10984056.001]
  • [Cites] Int J Dermatol. 2006 Jul;45(7):854-6 [16863526.001]
  • [Cites] Dermatol Surg. 2005 Jan;31(1):16-8 [15720089.001]
  • [Cites] J Invest Dermatol. 2006 Jun;126(6):1251-5 [16557235.001]
  • [Cites] J Am Acad Dermatol. 1997 Jan;36(1):72-7 [8996264.001]
  • [Cites] Dermatol Surg. 2003 Nov;29(11):1150-3; discussion 1153 [14641346.001]
  • [Cites] J Dtsch Dermatol Ges. 2006 Feb;4(2):108-13 [16503937.001]
  • [Cites] J Photochem Photobiol B. 1992 Jul 30;14 (4):275-92 [1403373.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):125-43 [17190630.001]
  • [Cites] Arch Dermatol. 2004 Dec;140(12 ):1542 [15611446.001]
  • [Cites] Br J Dermatol. 2004 Oct;151(4):837-45 [15491425.001]
  • [Cites] J Natl Cancer Inst. 2003 Aug 6;95(15):1138-49 [12902443.001]
  • [Cites] Anticancer Drugs. 2006 Oct;17(9):1095-8 [17001184.001]
  • [Cites] Dermatol Clin. 2007 Jan;25(1):5-14 [17126737.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1306-11 [10728691.001]
  • [Cites] Br J Dermatol. 2003 Dec;149(6):1242-9 [14674903.001]
  • [Cites] Lasers Surg Med. 2007 Apr;39(4):302-10 [17457834.001]
  • [Cites] Dermatol Clin. 2007 Jan;25(1):15-23 [17126738.001]
  • [Cites] Br J Dermatol. 2000 Oct;143(4):843-5 [11069469.001]
  • [Cites] Clin Ther. 2002 Jun;24(6):990-1000 [12117087.001]
  • [Cites] J Dtsch Dermatol Ges. 2006 Feb;4(2):132-6 [16503940.001]
  • [Cites] J Am Acad Dermatol. 2001 May;44(5):807-13 [11312429.001]
  • [Cites] Int J Dermatol. 2005 May;44(5):428-34 [15869545.001]
  • (PMID = 19322549.001).
  • [ISSN] 1433-0458
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 77
  •  go-up   go-down


14. Mosterd K, Krekels GA, Nieman FH, Ostertag JU, Essers BA, Dirksen CD, Steijlen PM, Vermeulen A, Neumann H, Kelleners-Smeets NW: Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncol; 2008 Dec;9(12):1149-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up.
  • BACKGROUND: Basal-cell carcinoma (BCC) is the most common form of skin cancer and its incidence is still rising worldwide.
  • We did a prospective randomised controlled trial to compare the effectiveness of surgical excision with Mohs' micrographic surgery (MMS) for the treatment of primary and recurrent facial BCC.
  • The primary outcome was recurrence of carcinoma, diagnosed clinically by visual inspection with histological confirmation.
  • This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN65009900.
  • The difference in the number of recurrences between treatments was not significant for pBCC, but significantly favoured MMS in rBCC.
  • In pBCC, Cox-regression analysis showed no significant effects from risk factors measured in the study.
  • INTERPRETATION: MMS is preferred over surgical excision for the treatment of facial rBCC, on the basis of significantly fewer recurrences after MMS than after surgical excision.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Facial Neoplasms / surgery. Health Care Costs. Mohs Surgery / economics. Neoplasm Recurrence, Local / surgery. Skin Neoplasms / surgery


15. Diluvio L, Campione E, Paternò EJ, Orlandi A, Terrinoni A, Chimenti S: Peculiar clinical and dermoscopic remission pattern following imiquimod therapy of basal cell carcinoma in seborrhoeic areas of the face. J Dermatolog Treat; 2009;20(2):124-9
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peculiar clinical and dermoscopic remission pattern following imiquimod therapy of basal cell carcinoma in seborrhoeic areas of the face.
  • Imiquimod is a 240.3-Da synthetic imidazoquinolinamine (C14H16N4), developed in 1983 and approved in 1997 by the US Food and Drug Administration for the topical treatment of external genital and perianal warts and, more recently, also for actinic keratosis and superficial basal cell carcinomas.
  • We report five cases of patients affected by basal cell carcinomas localized in seborrhoeic areas of the face, successfully treated with topical imiquimod and characterized by the occurrence of eruptive epidermoid cysts at the end-point of therapy.
  • The dermatoscopic evaluation disclosed the presence in all lesions of a common feature characterized by a hyperkeratotic yellow-withish area, resembling 'popcorn', excluding dermoscopic basal cell carcinoma features.
  • Furthermore, histological proof confirmed the diagnosis of epidermoid cysts.
  • As reported in the literature and as observed in our clinical experience, the occurrence of epidermoid cysts, after the topical treatment of basal cell carcinomas with imiquimod, may represent a local immune reaction that is drug-related and is a typical remission pattern in particular anatomical areas.
  • We also emphasized the usefulness of dermoscopy in supporting the clinical diagnosis of epidermoid cysts, excluding the presence of tumoural residue or recurrence.
  • [MeSH-major] Aminoquinolines / therapeutic use. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / pathology. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology
  • [MeSH-minor] Administration, Cutaneous. Aged. Antineoplastic Agents / therapeutic use. Biopsy, Needle. Dermoscopy / methods. Dose-Response Relationship, Drug. Drug Administration Schedule. Face. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Risk Assessment. Sampling Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18991155.001).
  • [ISSN] 1471-1753
  • [Journal-full-title] The Journal of dermatological treatment
  • [ISO-abbreviation] J Dermatolog Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


16. Tatiana K S C, Somers GR, Pope E, Zuker RM: Predisposing factors and outcomes of malignant skin tumors in children. Plast Reconstr Surg; 2010 Aug;126(2):508-14
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predisposing factors and outcomes of malignant skin tumors in children.
  • BACKGROUND: Although benign and metastatic tumors occur in children, primary malignant skin tumors are uncommon in the pediatric population.
  • In this study, the authors aimed to determine the incidence, risk factors, treatment, reconstruction details, and outcome of malignant skin tumors occurring in pediatric patients at the Hospital for Sick Children.
  • METHODS: The electronic database (CoPath) of the pathology department was searched for all cases of malignant skin tumors treated surgically between January of 2000 and September of 2008.
  • RESULTS: Eighteen patients had been diagnosed and treated surgically for malignant skin tumors.
  • Diagnosis of malignant melanoma was made in 14 patients, diagnosis of basal cell carcinoma was made in four patients, and diagnosis of squamous cell carcinoma was made in one patient.
  • The most common sites of occurrence were lower limbs (33 percent) and face (28 percent).
  • Gorlin syndrome was an underlying predisposing condition in three patients with basal cell carcinoma.
  • All cases of basal cell carcinoma and squamous cell carcinoma underwent surgical resection and primary closure or skin graft.
  • Of the patients with malignant melanoma, seven underwent surgical excision and primary closure and five had excision and skin graft.
  • One patient with melanoma suffered a recurrence.
  • CONCLUSIONS: Malignant skin tumors are rare in children.
  • In accordance with previously published data, malignant melanoma was the most frequent tumor in our study.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Sentinel Lymph Node Biopsy / methods. Skin Neoplasms / epidemiology. Skin Neoplasms / surgery. Skin Transplantation / methods
  • [MeSH-minor] Adolescent. Age Distribution. Canada / epidemiology. Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Causality. Child. Child, Preschool. Cohort Studies. Databases, Factual. Dermatology / methods. Female. Follow-Up Studies. Humans. Immunohistochemistry. Incidence. Male. Melanoma / epidemiology. Melanoma / pathology. Melanoma / surgery. Neoplasm Staging. Sex Distribution. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20375763.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Abedalthagafi M, Rushing EJ, Auerbach A, Desouki MM, Marwaha J, Wang Z, Fanburg-Smith JC: Sporadic cutaneous angiosarcomas generally lack hypoxia-inducible factor 1alpha: a histologic and immunohistochemical study of 45 cases. Ann Diagn Pathol; 2010 Feb;14(1):15-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic cutaneous angiosarcomas generally lack hypoxia-inducible factor 1alpha: a histologic and immunohistochemical study of 45 cases.
  • Cutaneous angiosarcoma (AS) is a rare malignant neoplasm of dermis composed of infiltrating cells of endothelial phenotype with overall poor prognosis.
  • Although autocrine stimulation by vascular endothelial growth factor secretion may play a role in the pathogenesis of angiosarcoma, its mechanism has not been fully established.
  • Cases coded as "angiosarcoma" of dermis were culled and re-reviewed for inclusion as AS, based on patient folder, slides, and obtained immunohistochemistry including CD31 and smooth muscle actin (SMA).
  • Tumors presented most commonly in the skin of the scalp followed by the left lower leg, face, nose, lower arm, neck, thigh, eyelid, ear, and temple.
  • Associated basal cell carcinoma was noted in 1 patient; no others had other neoplasms or unrelated surgeries.
  • Epithelioid morphology was present in 29% (n = 13) cases.
  • CD31 highlighted malignant endothelial cells.
  • Treatment and follow-up data were only available on 4 cases: 2 died of disease within 4 years, 2 others had known recurrence within 2 years.
  • Requirement for diagnosis includes extravascular proliferation of atypical endothelial cells with mitotic activity in vasoformative, solid, and papillary patterns.
  • Absence of SMA can prove extravascular extension of tumor, outside their normal vessel confines.
  • Accordingly, the hypoxic response pathway is not thought to be a documentable common mechanism of angiogenesis in this entity.
  • [MeSH-major] Dermis / metabolism. Hemangiosarcoma / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Neovascularization, Pathologic / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anoxia / metabolism. Anoxia / pathology. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Inc.
  • (PMID = 20123452.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit
  •  go-up   go-down


18. Hendi A, Brodland DG, Zitelli JA: Melanocytes in long-standing sun-exposed skin: quantitative analysis using the MART-1 immunostain. Arch Dermatol; 2006 Jul;142(7):871-6
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanocytes in long-standing sun-exposed skin: quantitative analysis using the MART-1 immunostain.
  • OBJECTIVE: To help distinguish early melanoma from normal sun-damaged skin by quantifying the density, confluence, and depth of follicular penetration of melanocytes in long-standing sun-exposed skin of the face and neck.
  • PATIENTS: Random selection of 149 patients undergoing Mohs surgery for basal cell and squamous cell carcinomas of the face and neck.
  • INTERVENTION: Frozen-section slides were made from long-standing sun-exposed normal skin and stained with MART-1 (melanoma antigen recognized by T cells 1 staining) immunostain.
  • MAIN OUTCOME MEASURES: The number, confluence, and depth of penetration of melanocytes along the follicular epithelium were quantified per high-power field (original magnification x 400, equivalent to 0.5 mm of skin).
  • Pagetoid spread and nesting of melanocytes were not seen.
  • CONCLUSIONS: Melanocytes in long-standing sun-exposed skin have an increased density and a confluence that is often moderate (3-6 adjacent melanocytes), but they do not exhibit pagetoid spread or nesting.
  • Nonspecific MART-1-staining dermal cells should not be interpreted as invasive melanoma.
  • [MeSH-major] Antigens, Neoplasm. Melanocytes / cytology. Melanoma / diagnosis. Neoplasm Proteins. Skin / radiation effects. Skin Neoplasms / diagnosis. Sunlight
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. MART-1 Antigen. Male. Middle Aged. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16847203.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Neoplasm Proteins
  •  go-up   go-down


19. Ntomouchtsis A, Vahtsevanos K, Patrikidou A, Andreadis C, Tsobanidou C, Antoniades K: Adnexal skin carcinomas of the face. J Craniofac Surg; 2009 Jan;20(1):134-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adnexal skin carcinomas of the face.
  • Skin adnexal neoplasms are rare tumors, and knowledge on their exact histological development and pathogenesis remains fragmented.
  • Their diagnosis and management are frequently troublesome, especially for malignant tumors.
  • We present a retrospective case series of malignant appendageal tumors of the face.
  • Records of patients with histologically confirmed adnexal skin carcinoma managed at a single department during the period 1995 to 2004 were reviewed.
  • Patient biodata, surgical management, and main outcome measures such as locoregional recurrence, distant metastasis, and disease-free and overall survival were recorded.Eleven patients were identified from record analysis.
  • Nine of 11 patients were alive and free of local and/or regional disease on final follow-up.
  • Two patients died of causes unrelated to the disease.
  • Clinical and histological features, tumor biological behavior, diagnostic difficulties, and recommended management are discussed.In conclusion, adnexal skin tumors should be considered in the differential diagnosis of skin tumors, particularly in view of their more sinister prognosis compared with other nonmelanoma skin tumors.
  • [MeSH-major] Carcinoma, Skin Appendage / surgery. Facial Neoplasms / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Cohort Studies. Diagnosis, Differential. Disease-Free Survival. Eyelid Neoplasms / surgery. Female. Follow-Up Studies. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neck Dissection. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / pathology. Nose Neoplasms / surgery. Retrospective Studies. Surgical Flaps. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19165010.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Gayre GS, Hybarger CP, Mannor G, Meecham W, Delfanti JB, Mizono GS, Guerry TL, Chien JS, Sooy CD, Anooshian R, Simonds R, Pietila KA, Smith DW, Dayhoff DA, Engman E, Lacy J: Outcomes of excision of 1750 eyelid and periocular skin basal cell and squamous cell carcinomas by modified en face frozen section margin-controlled technique. Int Ophthalmol Clin; 2009;49(4):97-110
MedlinePlus Health Information. consumer health - Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of excision of 1750 eyelid and periocular skin basal cell and squamous cell carcinomas by modified en face frozen section margin-controlled technique.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Facial Neoplasms / surgery. Frozen Sections / methods. Skin Neoplasms / surgery. Surgical Procedures, Operative / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Incidence. Intraoperative Period. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Retrospective Studies. Time Factors. Treatment Outcome. United States / epidemiology. Young Adult

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20348860.001).
  • [ISSN] 1536-9617
  • [Journal-full-title] International ophthalmology clinics
  • [ISO-abbreviation] Int Ophthalmol Clin
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement